Dopamine

CLINICAL USE

Treatment of dementia in mild to moderate Alzheimer’s disease

DOSE IN NORMAL RENAL FUNCTION

5–10 mg daily

PHARMACOKINETICS

  • Molecular weight                           :416
  • %Protein binding                           :95
  • %Excreted unchanged in urine     : 17
  • Volume of distribution (L/kg)       :12
  • half-life – normal/ESRD (hrs)      :70/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unlikely to be dialysed. Dose as in normal renal function
  • HD                     :Unlikely to be dialysed. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsNone known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Metabolised via CYP450 3A4 and 2D6 so may interact with other drugs metabolised by these pathways

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia